These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

391 related items for PubMed ID: 33301466

  • 1. A combination of urinary biomarker panel and PancRISK score for earlier detection of pancreatic cancer: A case-control study.
    Debernardi S, O'Brien H, Algahmdi AS, Malats N, Stewart GD, Plješa-Ercegovac M, Costello E, Greenhalf W, Saad A, Roberts R, Ney A, Pereira SP, Kocher HM, Duffy S, Blyuss O, Crnogorac-Jurcevic T.
    PLoS Med; 2020 Dec; 17(12):e1003489. PubMed ID: 33301466
    [Abstract] [Full Text] [Related]

  • 2. Development of PancRISK, a urine biomarker-based risk score for stratified screening of pancreatic cancer patients.
    Blyuss O, Zaikin A, Cherepanova V, Munblit D, Kiseleva EM, Prytomanova OM, Duffy SW, Crnogorac-Jurcevic T.
    Br J Cancer; 2020 Mar; 122(5):692-696. PubMed ID: 31857725
    [Abstract] [Full Text] [Related]

  • 3. Identification of a Three-Biomarker Panel in Urine for Early Detection of Pancreatic Adenocarcinoma.
    Radon TP, Massat NJ, Jones R, Alrawashdeh W, Dumartin L, Ennis D, Duffy SW, Kocher HM, Pereira SP, Guarner posthumous L, Murta-Nascimento C, Real FX, Malats N, Neoptolemos J, Costello E, Greenhalf W, Lemoine NR, Crnogorac-Jurcevic T.
    Clin Cancer Res; 2015 Aug 01; 21(15):3512-21. PubMed ID: 26240291
    [Abstract] [Full Text] [Related]

  • 4. Urinary biomarkers analysis as a diagnostic tool for early detection of pancreatic adenocarcinoma: Molecular quantification approach.
    Samir S, El-Ashry M, Soliman W, Hassan M.
    Comput Biol Chem; 2024 Oct 01; 112():108171. PubMed ID: 39159599
    [Abstract] [Full Text] [Related]

  • 5. Validation of four candidate pancreatic cancer serological biomarkers that improve the performance of CA19.9.
    Makawita S, Dimitromanolakis A, Soosaipillai A, Soleas I, Chan A, Gallinger S, Haun RS, Blasutig IM, Diamandis EP.
    BMC Cancer; 2013 Sep 03; 13():404. PubMed ID: 24007603
    [Abstract] [Full Text] [Related]

  • 6. Urine biomarkers enable pancreatic cancer detection up to 2 years before diagnosis.
    Debernardi S, Blyuss O, Rycyk D, Srivastava K, Jeon CY, Cai H, Cai Q, Shu XO, Crnogorac-Jurcevic T.
    Int J Cancer; 2023 Feb 15; 152(4):769-780. PubMed ID: 36093581
    [Abstract] [Full Text] [Related]

  • 7. Plasma miRNA Biomarkers in Limited Volume Samples for Detection of Early-stage Pancreatic Cancer.
    Dittmar RL, Liu S, Tai MC, Rajapakshe K, Huang Y, Longton G, DeCapite C, Hurd MW, Paris PL, Kirkwood KS, Coarfa C, Maitra A, Brand RE, Killary AM, Sen S.
    Cancer Prev Res (Phila); 2021 Jul 15; 14(7):729-740. PubMed ID: 33893071
    [Abstract] [Full Text] [Related]

  • 8. Plasma protein biomarkers for early detection of pancreatic ductal adenocarcinoma.
    Yu J, Ploner A, Kordes M, Löhr M, Nilsson M, de Maturana MEL, Estudillo L, Renz H, Carrato A, Molero X, Real FX, Malats N, Ye W.
    Int J Cancer; 2021 Apr 15; 148(8):2048-2058. PubMed ID: 33411965
    [Abstract] [Full Text] [Related]

  • 9. THBS2/CA19-9 Detecting Pancreatic Ductal Adenocarcinoma at Diagnosis Underperforms in Prediagnostic Detection: Implications for Biomarker Advancement.
    Udgata S, Takenaka N, Bamlet WR, Oberg AL, Yee SS, Carpenter EL, Herman D, Kim J, Petersen GM, Zaret KS.
    Cancer Prev Res (Phila); 2021 Feb 15; 14(2):223-232. PubMed ID: 33067248
    [Abstract] [Full Text] [Related]

  • 10. A Plasma Biomarker Panel to Identify Surgically Resectable Early-Stage Pancreatic Cancer.
    Balasenthil S, Huang Y, Liu S, Marsh T, Chen J, Stass SA, KuKuruga D, Brand R, Chen N, Frazier ML, Jack Lee J, Srivastava S, Sen S, McNeill Killary A.
    J Natl Cancer Inst; 2017 Aug 01; 109(8):. PubMed ID: 28376184
    [Abstract] [Full Text] [Related]

  • 11. Reg proteins promote acinar-to-ductal metaplasia and act as novel diagnostic and prognostic markers in pancreatic ductal adenocarcinoma.
    Li Q, Wang H, Zogopoulos G, Shao Q, Dong K, Lv F, Nwilati K, Gui XY, Cuggia A, Liu JL, Gao ZH.
    Oncotarget; 2016 Nov 22; 7(47):77838-77853. PubMed ID: 27788482
    [Abstract] [Full Text] [Related]

  • 12. Evaluation of urinary C-reactive protein as an early detection biomarker for pancreatic ductal adenocarcinoma.
    Ali N, Debernardi S, Kurotova E, Tajbakhsh J, Gupta NK, Pandol SJ, Wilson P, Pereira SP, Greenhalf B, Blyuss O, Crnogorac-Jurcevic T.
    Front Oncol; 2024 Nov 22; 14():1450326. PubMed ID: 39309742
    [Abstract] [Full Text] [Related]

  • 13. Sequential Validation of Blood-Based Protein Biomarker Candidates for Early-Stage Pancreatic Cancer.
    Capello M, Bantis LE, Scelo G, Zhao Y, Li P, Dhillon DS, Patel NJ, Kundnani DL, Wang H, Abbruzzese JL, Maitra A, Tempero MA, Brand R, Firpo MA, Mulvihill SJ, Katz MH, Brennan P, Feng Z, Taguchi A, Hanash SM.
    J Natl Cancer Inst; 2017 Apr 01; 109(4):. PubMed ID: 28376157
    [Abstract] [Full Text] [Related]

  • 14. Serum cytokine biomarker panels for discriminating pancreatic cancer from benign pancreatic disease.
    Shaw VE, Lane B, Jenkinson C, Cox T, Greenhalf W, Halloran CM, Tang J, Sutton R, Neoptolemos JP, Costello E.
    Mol Cancer; 2014 May 20; 13():114. PubMed ID: 24884871
    [Abstract] [Full Text] [Related]

  • 15. Development of serum parameters panels for the early detection of pancreatic cancer.
    Zhang P, Zou M, Wen X, Gu F, Li J, Liu G, Dong J, Deng X, Gao J, Li X, Jia X, Dong Z, Chen L, Wang Y, Tian Y.
    Int J Cancer; 2014 Jun 01; 134(11):2646-55. PubMed ID: 24615168
    [Abstract] [Full Text] [Related]

  • 16. Identification of Serum Biomarker Panels for the Early Detection of Pancreatic Cancer.
    Song J, Sokoll LJ, Pasay JJ, Rubin AL, Li H, Bach DM, Chan DW, Zhang Z.
    Cancer Epidemiol Biomarkers Prev; 2019 Jan 01; 28(1):174-182. PubMed ID: 30333219
    [Abstract] [Full Text] [Related]

  • 17. A unique urinary metabolomic signature for the detection of pancreatic ductal adenocarcinoma.
    Sahni S, Pandya AR, Hadden WJ, Nahm CB, Maloney S, Cook V, Toft JA, Wilkinson-White L, Gill AJ, Samra JS, Dona A, Mittal A.
    Int J Cancer; 2021 Mar 15; 148(6):1508-1518. PubMed ID: 33128797
    [Abstract] [Full Text] [Related]

  • 18. Periostin and CA242 as potential diagnostic serum biomarkers complementing CA19.9 in detecting pancreatic cancer.
    Dong D, Jia L, Zhang L, Ma N, Zhang A, Zhou Y, Ren L.
    Cancer Sci; 2018 Sep 15; 109(9):2841-2851. PubMed ID: 29945294
    [Abstract] [Full Text] [Related]

  • 19. Identification of a serum proteomic biomarker panel using diagnosis specific ensemble learning and symptoms for early pancreatic cancer detection.
    Ney A, Nené NR, Sedlak E, Acedo P, Blyuss O, Whitwell HJ, Costello E, Gentry-Maharaj A, Williams NR, Menon U, Fusai GK, Zaikin A, Pereira SP.
    PLoS Comput Biol; 2024 Aug 15; 20(8):e1012408. PubMed ID: 39208354
    [Abstract] [Full Text] [Related]

  • 20. A rigorous multi-laboratory study of known PDAC biomarkers identifies increased sensitivity and specificity over CA19-9 alone.
    Haab B, Qian L, Staal B, Jain M, Fahrmann J, Worthington C, Prosser D, Velokokhatnaya L, Lopez C, Tang R, Hurd MW, Natarajan G, Kumar S, Smith L, Hanash S, Batra SK, Maitra A, Lokshin A, Huang Y, Brand RE.
    Cancer Lett; 2024 Nov 01; 604():217245. PubMed ID: 39276915
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 20.